Synthetic biotechnology company Bluepha closes multi-million-yuan Series A+ round

Synthetic biotechnology company Bluepha has recently received tens of millions of yuan in its Series A+ financing round, and the investor was Green Pine Capital Partners.

Synthetic biotechnology company Bluepha has recently received tens of millions of yuan in its Series A+ financing round, and the investor was Green Pine Capital Partners.

Zhang Haoqian, co-founder and CEO of Bluepha, said that the proceeds from the latest funding round will mainly be used to improve the deployment of the biological research and development automation system Holog and accelerate the industrialization of existing product pipelines.

Bluepha focus on the research and development and innovative application of synthetic biotechnology. They mainly provide customized research programs for biological functional molecules and new functional materials, including fully degradable biological materials PHA, plant natural drug molecules and novel in-vitro diagnostic reagents.

In February 2017, Bluepha had received millions of yuan in an angel round led by Frees Fund. In May 2018, the company obtained 10 million yuan in Pre-A financing round, led by Leaguer Venture Investment, with participation from angel round investor Frees Fund. In November 2019, it announced that it had secured 40 million yuan in its Series A financing round.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/05/29/synthetic-biotechnology-company-bluepha-closes-multi-million-yuan-series-a-round/.

Leave a Reply

Please Login to Comment